AEGR-733

DRUG3 trials

Sponsors

Aegerion Pharmaceuticals, Inc.

Conditions

Homozygous Familial HypercholesterolemiaHypercholesterolemiaHyperlipidemia

Phase 2

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

CompletedNCT00559962

Aegerion Pharmaceuticals, Inc.Hyperlipidemia

Start: 2007-10-31End: 2008-11-30Updated: 2018-02-23

Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia

CompletedNCT00690443

Aegerion Pharmaceuticals, Inc.Hypercholesterolemia

Start: 2008-05-31End: 2008-09-30Updated: 2018-02-23

Phase 3

A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)

CompletedNCT00730236

Aegerion Pharmaceuticals, Inc.Homozygous Familial Hypercholesterolemia

Start: 2007-12-31End: 2011-10-31Updated: 2018-03-20

Related Papers

Lomitapide modifies high-density lipoprotein function in homozygous familial hypercholesterolaemia.

2025-04-11

Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia

Liver International2022-12-1532 citations

Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia.

2018-06-2034 citations

Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort.

2015-11-1112 citations